175 completed, 48 recruiting, 31 unknown, 24 terminated. 73 Phase 3, 60 Phase 4, 46 Phase 2, 35 Phase 1, 25 Not applicable.
Follow apixaban: new trials by email Literature Review of apixaban trials Research Report on apixaban
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus Continue rivaroxaban or apixaban or warfarin, Discontinue rivaroxaban or apixaban or warfarin - Left Ventricular Thrombus | Phase 2 | Not yet recruiting | Queen Mary University of London | 120 | 2026-12-01 | 2026-02-27 |
| Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism edoxaban, Apixaban - Venous Thromboembolism, Active Cancer | Phase 4 | Not yet recruiting | Samsung Medical Center | 2300 | 2026-11-01 | 2026-10-01 |
| Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis 2 (SAFE-D2) Eliquis, No oral anticoagulation - Atrial Fibrillation, Atrial Flutter | Phase 3 | Not yet recruiting | Unity Health Toronto | 848 | 2026-11-01 | 2026-08-21 |
| Oral Anticoagulation in Patients With Prior Deep Intracerebral Hemorrhage, Atrial Fibrillation, and Ischemic Stroke Apixaban, No Oral Anticoagulation Strategy - Intracerebral Hemorrhage, Atrial Fibrillation (AF) | Phase 4 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 852 | 2026-10-26 | 2026-10-20 |
| Vortosiran in Atrial Fibrillation Vortosiran, Apixaban - Non-valvular Atrial Fibrillation (AF) | Phase 2 | Not yet recruiting | Ribocure Pharmaceuticals AB | 150 | 2026-10-01 | 2026-10-13 |
| Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty Apixaban, Rivaroxaban, Enoxaparin (LMWH) - Total Knee Arthroplasty, Venous Thromboembolism | Not applicable | Recruiting | Military Hospital of Tunis | 138 | 2026-09-15 | 2026-10-16 |
| Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel) Apixaban - Coronary Artery Disease, High On-treatment Platelet Reactivity (HTPR) | Phase 4 | Active not recruiting | The University of The West Indies | 16 | 2026-09-03 | 2026-10-02 |
| Population Pharmacokinetics of Apixaban in Asian Patients With Atrial Fibrillation Apixaban - Non Valvular Atrial Fibrillation (nv AF) | Not yet recruiting | Chulalongkorn University | 200 | 2026-09-01 | 2026-08-05 | |
| Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion Half-Dose of novel OAC, Low-dose ASA - Atrial Fibrillation (AF) | Phase 3 | Recruiting | Texas Cardiac Arrhythmia Research Foundation | 234 | 2026-09-01 | 2026-10-05 |
| Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers REGN7508, Apixaban - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1600 | 2026-08-26 | 2026-10-21 |
| Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran, Aspirin - Stroke, Acute Ischemic Stroke | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 680 | 2026-08-15 | 2026-08-05 |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation REGN7508, Apixaban, Placebo - Atrial Fibrillation (AF) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 15364 | 2026-08-10 | 2026-10-08 |
| Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease Apixaban - Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT) | Phase 4 | Not yet recruiting | James Bayley | 50 | 2026-08-01 | 2026-07-20 |
| SWITCH: Apixaban vs Vitamin K in HM3 Warfarin, Apixaban - LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure | Phase 3 | Not yet recruiting | Columbia University | 460 | 2026-08-01 | 2026-08-31 |
| Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease Edoxaban, Apixaban - Atrial Fibrillation (AF), Coronary Arterial Disease (CAD) | Phase 4 | Recruiting | Samsung Medical Center | 3000 | 2026-07-20 | 2026-08-10 |
| Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial Apixaban 2.5 mg twice daily, Placebo - Liver Cirrhosis | Phase 3 | Not yet recruiting | University College, London | 1142 | 2026-07-15 | 2026-07-24 |
| BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis Apixaban, Clopidogrel - Stroke, Ischemic | Phase 4 | Recruiting | Yonsei University | 586 | 2026-07-14 | 2026-10-16 |
| Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism Prophylaxis Apixaban, Enoxaparin - Postpartum, DVT Prophylaxis | Not applicable | Not yet recruiting | Ron Beloosesky MD | 150 | 2026-07-01 | 2026-07-21 |
| Apixaban Versus Warfarin for Left Ventricular Thrombus Apixaban, Warfarin - Left Ventricular Thrombus | Phase 3 | Recruiting | University of Arizona | 218 | 2026-06-22 | 2026-07-17 |
| STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism Anticoagulants, Thrombolytic Agents, Mechanical Thrombectomy Devices - Pulmonary Embolism, Venous Thromboembolism | Not yet recruiting | Nanjing First Hospital, Nanjing Medical University | 1300 | 2026-06-01 | 2026-05-22 |
Showing 20 of 315. Sign in to see all of them.
Atrial Fibrillation (83) · Venous Thromboembolism (60) · Venous Thrombosis (35) · Stroke (32) · Thrombosis (28) · Pulmonary Embolism (27) · Hemorrhage (20) · Ischemic Stroke (19) · Neoplasms (15) · Kidney Failure, Chronic (9) · Thromboembolism (8) · COVID-19 (7) · Cerebral Hemorrhage (7) · Fibrosis (7) · Hemostatic Disorders (6)
Bristol-Myers Squibb (43) · Pfizer (17) · Bayer (15) · Assistance Publique - Hôpitaux de Paris (7) · Brigham and Women's Hospital (6) · Ottawa Hospital Research Institute (6) · Mayo Clinic (5) · Regeneron Pharmaceuticals (5) · Northern Jiangsu People's Hospital (4) · Population Health Research Institute (4) · Canadian Network for Observational Drug Effect Studies, CNODES (3) · Portola Pharmaceuticals (3) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · Thomas Jefferson University (3) · Yonsei University (3)
United States (114) · Canada (56) · United Kingdom (44) · France (39) · Germany (37) · Spain (36) · Italy (35) · South Korea (29) · Israel (27) · Denmark (25) · Belgium (24) · Poland (24) · Sweden (23) · Australia (22) · Austria (22)
Lana Castellucci, MD, FRCPC (3) · Shirley Wang, PhD, ScM (3) · Daniel Crona, PharmD, PhD (2) · Dou-Sheng Bai (2) · Gunnar H Gislason, MD, PhD (2) · Madeleine Durand, MD, MSc, FRCPC (2) · Min Lou, PhD, MD (2) · Robert D McBane (2) · Samuel Asirvatham, MD (2) · Walter K Kraft, MD (2)
PMID 35570249, PMID 36700520, PMID 34022170, PMID 26188837, PMID 37591523, PMID 40302153, PMID 23279103, PMID 23808982, PMID 26867832, PMID 27292282, PMID 31630479, PMID 31867054, PMID 33337539, PMID 34172290, PMID 34622445, PMID 42389777, PMID 10582984, PMID 10591382, PMID 10737280, PMID 10905241, PMID 10963635, PMID 11546885, PMID 12393647, PMID 12917889, PMID 17258667, PMID 17272772, PMID 17332445, PMID 17525387, PMID 17635708, PMID 17635709, PMID 17702958, PMID 18190818, PMID 18388338, PMID 18664970, PMID 18705914, PMID 18815396, PMID 18840838, PMID 19078910, PMID 19470889, PMID 19590057, PMID 19657123, PMID 19718469, PMID 19764826, PMID 19817986, PMID 20075341, PMID 20124539, PMID 20206776, PMID 20665856, PMID 20694281, PMID 20723861
2014 (8), 2016 (5), 2023 (5), 2017 (4), 2025 (4), 2015 (2), 2019 (2), 2018 (1), P30CA015083 (1), R34HL113404 (1), U01NS095869 (1), U01NS106513 (1)